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Summary
Larvae	 of	 Schistosoma	 (schistosomula)	 are	 highly	 susceptible	 to	 host	 immune	 re-
sponses and are attractive prophylactic vaccine targets, although cellular immune 
responses against schistosomula antigens in endemic human populations are not well 
characterized. We collected blood and stool from 54 Schistosoma mansoni-	infected	
Ugandans,	 isolated	 peripheral	 blood	 mononuclear	 cells	 and	 stimulated	 them	 for	
24	hours	with	 schistosome	 adult	worm	 and	 soluble	 egg	 antigens	 (AWA	and	 SEA),	
along	with	schistosomula	recombinant	proteins	rSmKK7,	Lymphocyte	Antigen	6	iso-
forms	 (rSmLy6A	 and	 rSmLy6B),	 tetraspanin	 isoforms	 (rSmTSP6	 and	 rSmTSP7).	
Cytokines,	chemokines	and	growth	factors	were	measured	in	the	culture	superna-
tants	using	a	multiplex	luminex	assay,	and	infection	intensity	was	determined	before	
and	at	1	year	after	praziquantel	(PZQ)	treatment	using	the	Kato-	Katz	method.	Cellular	
responses were grouped and the relationship between groups of correlated cellular 
responses	and	infection	intensity	before	and	after	PZQ	treatment	was	investigated.	
AWA	and	SEA	 induced	mainly	Th2	responses.	 In	contrast,	 rSmLy6B,	rSmTSP6	and	
rSmTSP7	 induced	 Th1/pro-	inflammatory	 responses.	 While	 recombinant	 antigens	
rSmKK7	and	rSmLy6A	did	not	induce	a	Th1/pro-	inflammatory	response,	they	had	an	
association	with	pre-	treatment	 infection	 intensity	 after	 adjusting	 for	 age	 and	 sex.	
Testing	 more	 schistosomula	 antigens	 using	 this	 approach	 could	 provide	 immune-	
epidemiology	 identifiers	necessary	 for	prioritizing	next	generation	 schistosomiasis	
vaccine candidates.
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution	License,	which	permits	use,	distribution	and	reproduction	in	any	medium,	
provided	the	original	work	is	properly	cited.
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1  | INTRODUC TION
There	are	currently	206.4	million	people	suffering	 from	schistoso-
miasis worldwide1 with the majority of infected individuals living 
in	Africa.	National	 control	programmes	 in	high-	risk	 countries	 such	
as	 Uganda	 treat	 infected	 school-	age	 children	 and	 adults	 through	
mass	drug	administration	(MDA),	using	the	drug	praziquantel	(PZQ).	
Although	the	MDA	programmes	have	a	high	coverage	in	the	targeted	
areas,	national	coverage	still	remains	relatively	low.	For	instance,	in	
2015 just over a third of the estimated 13.2 million people who re-
quired	treatment	 in	Uganda	were	reported	to	have	received	 it.1 In 
addition,	MDA	programmes	have	no	effect	on	recurrent	reinfections	
in hotspots of transmission.2 More unsettlingly, there are reports 
of	 reduced	 efficacy	 of	 PZQ	with	multiple	 rounds	 of	MDA.3,4	 This	
suggests	 that	MDA	 alone	 is	 insufficient	 to	 control	 morbidity	 and	
prevent	schistosomiasis	 transmission.	Therefore,	an	 integrated	ap-
proach with other interventions such as vaccines is required.5,6
A	few	schistosomiasis	vaccines,	such	as	Sh28GST,	Sm-TSP-	2	and	
Sm-	14	 are	 currently	 in	 early	 human	 clinical	 trials,7,8 although the 
trial	 data	 are	 not	 yet	 available.	 Therefore,	 novel	 schistosome	 vac-
cine antigens are still needed for the vaccine development pipeline. 
Schistosome	 larvae	within	 the	 vertebrate	 host	 (known	 as	 schisto-
somula)	are	susceptible	 to	host	 immune	 responses	 in	animal	mod-
els, and thus antigens from this stage are thought to be potential 
vaccine candidates.9-11	 The	 schistosomula	 develop	when	 infective	
free-	swimming	 fresh-	water	 larvae	 (cercariae)	 burrow	 through	 the	
host	 skin	 and	 lose	 their	 bifurcated	 tails	 in	 a	 process	 called	 trans-
formation.12	Additional	 structural	 changes,	 such	as	 the	 loss	of	 the	
cercarial	glycocalyx	coat	during	the	transformation	process,	expose	
the	developing	schistosomula	to	host-	mediated	immune	responses.	
As	the	skin-	stage	schistosomula	develop	into	the	 lung-	stage	schis-
tosomula and adult worms, they acquire host antigens13	 masking	
themselves from host immune effector mechanisms.14	By	targeting	
antigens	from	the	early	schistosomula,	it	might	be	possible	to	attack	
this stage and prevent infection of the host. Potential vaccine can-
didates	expressed	in	the	newly	transformed	schistosomula	 include	
SmKK7	 (Smp_194830),15,16	 SmLy6A	 (Smp_019350)	 and	 SmLy6B	
(Smp_105220)13,17	and	the	tetraspanins	SmTSP6	(Smp_059530)	and	
SmTSP7	(Smp_099770).18,19
SmKK7	is	secreted	by	both	the	cercariae	and	the	schistosomula16; 
it has also been reported to be found in the nervous system of adult 
S. mansoni and to be homologous to a component in scorpion venom, 
acting	as	a	potassium	ion	channel	blocker.	Schistosoma mansoni lym-
phocyte	antigens,	rSmLy6A	and	rSmLy6B	(also	known	as	SmCD59a	
and	 SmCD59b),	 are	 members	 of	 the	 three-	finger	 protein	 domain	
(TFPD)	 superfamily.	 Although	 they	 are	 homologous	 to	 the	 TFPD-	
containing	human	CD59,	which	protects	human	cells	from	comple-
ment	fixation,	rSmLy6A	and	rSmLy6B	do	not	inhibit	host	complement	
fixation	and	as	such	their	function	remains	unknown.20	rSmLy6A	and	
rSmLy6B	are	highly	expressed	by	the	schistosomula,	and	as	probable	
GPI-	anchored	proteins	on	the	schistosome	tegument,	they	likely	in-
teract directly with host immune cells.21 Schistosoma mansoni trans-
membrane	proteins,	tetraspanins	rSmTSP6	and	rSmTSP7,	similarly	to	
other tetraspanin family members, are thought to be involved in cell 
membrane biology.19,22	 As	 all	 of	 the	 proteins	 described	 above	 are	
at the interface between the parasite and the host immune system, 
and thus may be novel vaccine antigens, we assessed the cellular 
responses to these antigens in individuals residing in an S. mansoni 
endemic area.
2  | MATERIAL S AND METHODS
2.1 | Ethics statement
Ethical	 approval	 for	 the	 study	 was	 obtained	 from	 the	 Makerere	
University	School	of	Biomedical	Sciences	Higher	Degrees	Research	
and	Ethics	Committee	(reference	number	SBS	300)	and	the	Uganda	
National	Council	for	Science	and	Technology	(reference	number	HS	
1040).	A	signed	informed	consent	form	was	obtained	from	partici-
pants, or parents or legal guardians of children below 18 years of 
age, for enrolment in the study.
2.2 | Recruitment of study participants
We	examined	 immune	responses	 in	peripheral	blood	mononuclear	
cells	 (PBMCs)	 of	 participants	 from	 TheSchistoVac	 study	 (http://
www.theschistovac.eu)	which	aimed	to	develop	safe	candidates	for	
a	prophylactic	schistosomiasis	vaccine.	The	design	of	TheSchistoVac	
study is described elsewhere.23	Briefly,	a	cohort	of	372	people	from	
an S. mansoni	 endemic	 fishing	village,	Namoni,	 in	Mayuge	District,	
Eastern	 Uganda,	 were	 recruited	 in	 September	 2011;	 infected	 in-
dividuals	were	 treated	with	 two	doses	of	PZQ	 (40	mg/kg)	 1	week	
apart	and	followed	up	at	5	weeks	and	at	1	year	after	PZQ	treatment.	
Venous	 blood	 was	 drawn	 before	 treatment	 and	 peripheral	 blood	
mononuclear	cells	(PBMCs)	isolated	by	density	gradient	centrifuga-
tion	using	Lymphoprep™	 (STEMCELL	Technologies	 Inc,	Cambridge,	
MA,	USA)	and	cryopreserved	in	liquid	nitrogen.	Here,	we	report	pre-	
treatment cellular immune responses in 54 participants from the co-
hort described above.
2.3 | Microscopic examination of stool for ova
Stool	 samples	were	collected	before	 treatment	 (to	determine	pre-	
treatment	infection	intensity),	5	weeks	after	treatment	(to	examine	
effectiveness	of	the	treatment)	and	at	1	year	after	PZQ	treatment	(to	
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determine	reinfection).	Three	stool	samples	were	collected	on	three	
consecutive	 days	 from	 study	 participants.	 Two	 thick	 smears	were	
made	 from	 each	 of	 the	 stool	 samples,	 processed	 using	 the	 Kato-	
Katz	method24	and	examined	under	a	light	microscope	to	determine	
S. mansoni egg count.
2.4 | Schistosoma mansoni antigens
TheSchistoVac	 consortium	 provided	 the	 antigens	 used	 in	 this	
study.	 The	 antigens	 included	 S. mansoni adult worm antigen 
(AWA)25 and S. mansoni	soluble	egg	antigen	(SEA)25 as well as the 
S. mansoni	schistosomula-	enriched	recombinant	antigens	rSmKK7	
(smp_194830),	 rSmLy6A	 (smp_019350),	 rSmLy6B	 (smp_105220),	
rSmTSP6	 (smp_059530)	 and	 rSmTSP7	 (smp_099770).19	 The	 anti-
gens	used	in	the	present	study	are	summarized	in	Table	1.	These	
antigens	were	identified	as	highly	expressed	products	in	the	schis-
tosomula life cycle stage after screening the Schistosoma tran-
scriptome	 using	 a	 DNA	microarray,	 as	 previously	 described.17,19 
Specifically,	 a	 >5-	fold	 increase	 in	 expression	 when	 comparing	
normalized	expression	averages	from	snail	(egg,	miracidia,	mother	
sporocyst	 and	 daughter	 sporocyst)	 to	 schistosomula	 (3-	,	 24-	
hours,	 3-	 and	 6-	day	 schistosomula)	 life	 stages	 was	 observed.17 
Recombinant	antigens	were	expressed	in	Escherichia coli and puri-
fied	using	methods	as	previously	described	for	rSmKK7,14	rSmLy6A	
and	rSmLy6B.15	For	rSmTSP6	and	rSmTSP7,	84	and	78	amino	acids	
were	 expressed,	 representing	 the	 extracellular	 loop	 2	 of	 these	
proteins,	 respectively,	 as	 defined	 by	 TMHMM2.0	 software.26 
About	106-	189	 amino	 acid	of	 rSmTSP6	 and	108-	185	 amino	 acid	
of	rSmTSP7	were	expressed	using	the	same	vector,	expression	pa-
rameters	and	purification	methods	as	rSmLy6A	and	B.27	Endotoxin	
contamination of the recombinant antigens was determined by 
Limulus	amebocyte	lysate	(LAL)	assay	using	the	Pierce	LAL	chro-
mogenic	 endotoxin	 quantitation	 kit	 (Thermo	 Fisher,	 Pittsburgh,	
PA,	USA).	The	endotoxin	levels	were	7.56	endotoxin	units	(EU)/mg	
for	 rSmKK7,	 undetectable	 (<0.4	EU/mg)	 for	 rSmLy6A,	 0.892	EU/
mg	 for	 rSmLy6B,	 0.626	EU/mg	 for	 rSmTSP6	 and	0.42	EU/mg	 for	
rSmTSP7.	The	limit	of	detection	of	the	LAL	assay	was	0.4	EU/mg.
2.5 | PBMC stimulation
Peripheral blood mononuclear cells were thawed, rested for 6 hours 
and stimulated for 24 hours with a panel of S. mansoni antigens in 
RPMI	1640	Medium	(Thermo	Fischer):	AWA	(10	μg/mL),	SEA	(10	μg/
mL),	 rSmKK7	 (2	μg/mL),	 rSmLy6A	 (2	μg/mL),	 rSmLy6B	 (2	μg/mL),	
rSmTSP6	(2	μg/mL)	and	rSmTSP7	(2	μg/mL).	Due	to	a	limited	number	
of	PBMCs	available	per	 individuals	and	a	 large	number	of	antigens	
tested,	 each	 antigen	 was	 tested	 in	 singlicate.	 After	 24	hours,	 the	
supernatants	were	collected	and	stored	at	−80°C.	Medium	without	
stimulus was used as a negative control.
2.6 | Multiplex luminex assay
Supernatants	 were	 analysed	 for	 cytokines	 (IFN-	γ,	 L-	1β,	 IL-	1ra,	 IL-	
2,	 IL-	4,	 IL-	5,	 IL-	6,	 IL-	7,	 IL-	9,	 IL-	10,	 IL-	12,	 IL-	13,	 IL-	15,	 IL-	17	 and	TNF),	
chemokines	 (Eotaxin,	 IL-	8,	 IP-	10,	 MCP-	1,	 MIP1a,	 MIP1b,	 RANTES)	
and	 growth	 factors	 (bFGF,	GCSF,	GMCSF,	 PDGFbb,	VEGF)	 using	 a	
commercial	Bio-	Plex	Luminex	assay	(Bio-	Rad,	Hercules,	CA,	USA)	ac-
cording	to	the	manufacturers’	recommendations,	and	acquired	using	
Bio-	Plex	200	System	(Bio-	Rad).	Samples	below	the	limit	of	detection	
were assigned values corresponding to half of the lowest standard 
value and those above the highest limit of detection were given the 
value	of	the	highest	standard.	Cytokines	that	were	wholly	below	the	
lower	limit	of	the	assay	(IL-	4	and	IL-	7)	and	chemokines	wholly	above	
the	upper	 limit	of	 the	assay	 (MIP1α, MIP1β	 and	RANTES)	were	ex-
cluded	 from	 analysis.	 Samples	 from	unstimulated	PBMCs	 that	 pro-
duced	TNF	 levels	>100	pg/mL	were	also	excluded	 from	analysis,	 as	
these were considered unreliable28,29;	high	IL-	1β	and	IL-	1ra	levels	were	
observed in the same samples.
TABLE  1 The	list	of	recombinant	antigens	used	in	the	present	study
Name Alternative names
Schistosoma mansoni 
GeneDB identificationa
Predictions from protein 
data
Protein size 
(amino acids)b References
SmKK7 Smp_194830 Signal	peptide	predictedc
No	transmembrane	regions	
predictedd
79 15,16
SmLy6a SmCD59a,	SmCD59.1 Smp_019350 One transmembrane regions 
predictedd
126 13,20
SmLy6b SmCD59b,	SmCD59.2 Smp_105220 One transmembrane regions 
predictedd
124 13,20,21
SmTSP6 Smp_059530 Four	transmembrane	regions	
predictedd
196 18,19
SmTSP7 Smp_099770 Four	transmembrane	regions	
predictedd
225 18,19
aGeneDB	is	an	annotation	database	for	pathogens.58 
bProtein	data	retrieved	from	GeneDB.	
cDetermined	using	SignalP.	
dDetermined	using	TMHMM.	
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2.7 | Statistical data analysis
Statistical	analysis	was	carried	out	using	STATA	version	13	(StataCorp,	
College	 Station,	 TX,	 USA)	 and	 graphs	 drawn	 using	 GraphPad	
Prism	version	6.0g	(GraphPad	Software	Inc.,	San	Diego,	CA,	USA).	
Cytokine,	 chemokine	 and	 growth	 factor	 levels	 were	 not	 normally	
distributed	and	were,	therefore,	transformed	using	Box-	Cox	trans-
formation.30,31	 The	 paired	 Student’s	 t test was used to compare 
responses	 between	 antigen	 stimulated	 and	 unstimulated	 PBMCs.	
Because	 the	 mean	 cytokine/chemokine/growth	 factor	 levels	 of	
more	than	two	antigen-	stimulated	PBMCs	was	compared	to	that	of	
the	unstimulated	PBMCs,	the	error	rate	due	to	multiple	testing	was	
adjusted	by	considering	a	Bonferroni	correction,	taking	into	account	
the number of comparisons being made. In this instance, a P-	value	
of	0.007	(=	0.05/7,	the	number	of	antigens	in	the	study)	for	each	cy-
tokine/chemokine/growth	factor	was	taken	to	be	statistically	signifi-
cant. Responses showing significant variation from the unstimulated 
PBMCs	were	further	analysed.	Unsupervised	hierarchical	clustering	
of	the	immune	responses	using	Spearman	correlation	as	the	meas-
ure	of	similarity	was	performed	using	GENE-	E	(Broad	Institute	Inc.,	
Cambridge,	MA,	USA).	The	association	between	clusters	(groups	of	
correlated	immune	parameters)	and	infection	intensity	before	treat-
ment and following treatment was investigated using the global test 
version	5.29.1.	The	global	test	was	based	on	the	logistic	regression	
model	and	was	implemented	in	R	version	3.3.2	(The	R	Foundation,	
Vienna,	Austria).	For	 this	analysis,	 the	post-	treatment	 infection	 in-
tensity of the participants was classified into two groups: light, and 
moderate	to	heavy	infection	intensity,	rather	than	the	WHO	catego-
ries	(light/moderate/heavy	infection	intensity),	as	when	stratified	by	
the	three	WHO	categories	there	were	 insufficient	numbers	within	
the moderate and heavy infection intensity groups for statistical 
analysis.
3  | RESULTS
3.1 | Characteristics of the study population
Table	2	shows	the	demographics	of	 the	study	population.	The	age	
range	of	the	study	participants	was	6-	40	years	and	28	(51.9%)	were	
female.	 All	 study	 participants	 were	 infected	 with	 S. mansoni with 
most	 individuals	 having	 heavy	 infection	 intensity	 (76%)	 at	 base-
line.	 The	median	 infection	 intensity	was	 1412	 (interquartile	 range	
443-	2567)	eggs	per	gram	of	stool	at	baseline.	Five	weeks	after	PZQ	
treatment, all the participants had zero eggs, indicative of treatment 
success	(data	not	shown).	At	follow-	up	(1	year	after	PZQ	treatment),	
all	participants	were	re-	infected	with	most	(57.0%)	having	a	light	in-
fection intensity.
3.2 | Schistosoma mansoni adult worm and egg 
antigens induce Th2 responses
Whole parasite preparations of S. mansoni, particularly the egg anti-
gens,	are	known	to	induce	Th2	responses.27-29 We sought to validate 
our	protocol	by	examining	immune	responses	to	crude	parasite	prep-
arations	of	AWA	and	SEA.	As	 expected,	 and	 confirming	our	 analy-
sis approach, the adult worm and soluble egg antigens induced the 
production	of	significant	levels	of	IL-	5	and	IL-	13	compared	to	medium	
(Figure	1).	None	of	the	schistosomula	antigens	induced	significant	Th2	
cytokine	production,	with	the	exception	of	rSmTSP7	induced	IL-	13.
3.3 | Recombinant rSmLy6B, rSmTSP6 and rSmTSP7 
induce a Th1/Pro- inflammatory cytokine profile
Recombinant	 schistosomula	 antigens	 rSmLy6B,	 rSmTSP6	 and	
rSmTSP7	induced	significant	and	robust	pre-	treatment	cytokine	re-
sponses	characterized	by	Th1	(IFN-	γ),	pro-	inflammatory	(IL-	1β,	IL-	2,	
IL-	6,	 IL-	9,	 IL-	12,	 IL-	15,	 IL-	17	and	TNF)	 (Figure	2)	 and	 regulatory	 re-
sponses	(IL-	1ra	and	IL-	10)	compared	to	medium	(Figure	3).	Moreover,	
rSmLy6B,	rSmTSP6	and	rSmTSP7	induced	high	levels	of	chemokines	
(Figure	S1)	and	growth	factors	(Figure	S2).	Interestingly,	rSmKK7	and	
rSmLy6A	 in	 contrast	were	 associated	with	much	 lower	 responses	
and	 suppressed	 production	 of	 IL-	17,	 IL-	1ra,	 bFGF,	 GMCSF,	 GCSF	
compared	to	medium	(Figures	2	and	3,	Figures	S1	and	S2).
3.4 | Cytokine, chemokine and growth factor 
responses to schistosomula antigens cluster 
depending on the antigen
To	 provide	 a	 more	 global	 assessment	 of	 responses	 to	 schisto-
somula antigens in S. mansoni-	infected	 individuals,	 cytokine	
Age,	median	(range) 12	(6-	40)
Females,	n	(%) 28	(52)
Pre-	treatment	infection	intensity
Light	(1-	99	epg),	n	(%) 7	(13)
Moderate	(100-	399	epg),	n	(%) 6	(11)
Heavy	(400+	epg),	n	(%) 41	(76)
1-	year	follow-	up	infection	intensity
Light	(1-	99	epg),	n	(%) 31	(57)
Moderate	to	heavy	(100+	epg),	n	(%) 23	(43)
epg, eggs per gram.
TABLE  2 Characteristics	of	study	
population	(N	=	54)
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responses	were	grouped	together	using	Spearman	correlation	as	a	
similarity measure, to reduce the number of variables for statisti-
cal analyses.
Cytokine	responses	directed	against	schistosomula	recombinant	
proteins	grouped	into	six	clusters:	two	clusters	composed	of	individ-
ual	cytokines	(an	IFN-	γ	only	cluster	A	and	IL-	15	only	cluster	B);	two	
clusters	 composed	 of	 Th1/pro-	inflammatory/regulatory	 response	
responses	 to	 rSmTSP6	 and	 rSmTSP7	 (clusters	 C	 and	 F);	 a	 cluster	
composed	 mainly	 of	 Th1/pro-	inflammatory/regulatory	 response	
mainly	to	rSmLy6B	(cluster	D);	and	a	pro-	inflammatory	cluster	in	re-
sponse	to	rSmKK7,	SmLy6A	and	SmLy6B	(cluster	E)	(Figure	4).
Similarly,	 chemokine	 responses	 to	 the	 schistosomula	 antigens	
clustered	 around	 individual	 chemokines	 (clusters	A	 and	C)	 and	 an	
eotaxin/IL-	8	cluster	in	response	to	all	antigens	tested	(Figure	S3A).
Finally,	growth	factor	responses	clustered	around	responses	to	
rSmKK7	and	rSmLy6A	(cluster	A),	responses	to	rSmLy6B,	rSmTSP6	
and	 rSmTSP7	 (cluster	 B)	 and	 a	 single	 growth	 factor	 cluster	 for	
PDGFFbb	(cluster	C)	(Figure	S3B).
3.5 | Responses to rSmKK7 and 
rSmLy6A are positively associated with pre- treatment 
infection intensity
To	 explore	 whether	 clusters	 of	 pre-	treatment	 cellular	 responses	
were	 associated	 with	 infection	 intensity	 before	 or	 1	year	 post-	
treatment, the global test was performed.32	 This	 test	 examines	
the	association	between	clusters	(eg,	groups	of	correlated	immune	
parameters)	 and	 an	outcome	 (eg,	 pre-	treatment	or	 post-	treatment	
infection	 intensity).	 After	 adjusting	 for	 age	 and	 sex,	 a	 significant	
positive	association	between	pre-	treatment	infection	intensity	and	
responses	 to	 rSmKK7	 and	 rSmLy6a	 was	 found	 for	 the	 IFN-	γ cy-
tokine	cluster	(Table	3,	P	=	0.026),	for	the	eotaxin	chemokine	cluster	
(Table	S1,	P	=	0.020))	and	a	combination	of	growth	factors	(Table	S2,	
P	=	0.015).	No	significant	associations	were	found	between	clusters	
of	 immune	 response	and	1-	year	post-	treatment	 infection	 intensity	
(Table	3,	Tables	S1	and	S2).
4  | DISCUSSION
The	 schistosomula	 are	 vulnerable	 to	 host	 immune	 responses	
after transformation from the cercariae stage.33,34	 As	 a	 result,	
antigens of the early schistosomula have been suggested as po-
tential vaccine candidates.21,35	 Here	 we	 measured	 cytokine,	
chemokine	and	growth	factor	responses	to	a	selection	of	S. man-
soni	 schistosomula-	enriched	 antigens	 in	 endemic	 subjects	 with	
high	infection	intensity,	and	who	become	re-	infected	1	year	after	
successful treatment.
To	validate	our	 study,	we	 first	 looked	at	 immune	 responses	 to	
the	crude	parasite	antigen	preparations	AWA	and	SEA.	In	line	with	
previous studies amongst individuals from high endemicity areas,36-
38	we	found	predominant	Th2	cytokine	responses	characterized	by	
high	IL-	5	and	IL-	13.
Few	schistosomula	antigens	have	been	tested	in	S. mansoni en-
demic	 populations.	 A	 non-	inclusive	 list	 of	 these	 antigens	 includes	
Sm29	(also	known	as	SmLy6D)39	and	Sm1440,41 that have both been 
tested	 in	Brazil.	We	 found	 that	 three	 of	 the	 recombinant	 schisto-
somula	antigens	tested	(rSmLy6B,	rSmTSP6	and	rSmTSP7)	 induced	
strong	 Th1/pro-	inflammatory	 and	 regulatory	 responses	while	 two	
others	(rSmKK7,	and	rSmLy6A)	induced	low	responses	in	a	Ugandan	
S. mansoni	endemic	population.	Th1	and	pro-	inflammatory	cytokines	
have	been	 implicated	 in	antibody-	independent	killing	of	schistoso-
mula	by	stimulating	macrophages	to	produce	nitric	oxide	that	medi-
ates	the	killing	of	schistosomula	in	animal	models.42,43	Although	the	
observed	cytokine	responses	are	consistent	with	a	previous	study	in	
which	a	recombinant	schistosomulum	antigen,	rSm14,	 induced	sig-
nificant	levels	of	Th1/pro-	inflammatory	cytokines	at	72	hours	after	
stimulation,40 our study shows that these responses can be mea-
sured	earlier	at	24	hours.	An	early	response	to	the	schistosomulum	is	
necessary	due	to	its	transient	nature	in	the	tissues	including	the	skin.
The	generation	of	Th1	 responses	 is	 associated	with	protective	
immunity to S. mansoni.44	 For	 instance,	 the	 schistosomula	 antigen	
SmLy6D	(Sm29)	induces	Th1	and	pro-	inflammatory	cytokines	(IFN-	
γ,	 TNF	 and	 IL-	12)	 that	 protect	 vaccinated	 mice	 against	 challenge	
F IGURE  1 Box-	Cox	transformed	Th2	cytokine	levels	in	response	to	stimulation	of	PBMCs	from	Schistosoma mansoni-	infected	
participants	(n	=	54)	before	PZQ	treatment	with	AWA,	SEA	and	schistosomula	antigens	compared	with	medium	(A)	IL-	5	(B)	IL-	13.	Box	
and	whisker	plots	show	median,	interquartile	range,	maximum	and	minimum	of	cytokine	levels.	A	paired	Student’s	t test was used to test 
differences between medium and antigens. *P	<	0.05,	**P <	0.007,	***P	<	0.001,	****P	<	0.0001
m
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F IGURE  2 Box-	Cox	transformed	Th1	(A,	B)	and	pro-	inflammatory	(C-	I)	cytokine	levels	in	response	to	stimulation	of	PBMCs	from	
Schistosoma mansoni-	infected	participants	(n	=	54)	before	PZQ	treatment	with	AWA,	SEA	and	schistosomula	antigens	compared	with	
medium.	Box	and	whisker	plots	show	median,	interquartile	range,	maximum	and	minimum	of	cytokine	levels.	A	paired	Student’s	t test was 
used to test differences between medium and antigens. *P < 0.05, **P	<	0.007,	***P	<	0.001,	****P	<	0001
(A) (B) (C)
(D) (E) (F)
(G) (H) (I)
F IGURE  3 Box-	Cox	transformed	regulatory	cytokine	levels	in	response	to	stimulation	of	PBMCs	from	Schistosoma mansoni-	infected	
participants	(n	=	54)	before	PZQ	treatment	with	AWA,	SEA	and	schistosomula	antigens	compared	with	medium	(A)	IL-	1ra	and	(B)	IL-	10.	Box	
and	whisker	plots	show	median,	interquartile	range,	maximum	and	minimum	of	cytokine	levels.	A	paired	Student’s	t test was used to test 
differences between medium and antigens. *P	<	0.05,	**P	<	0.007,	***P	<	0.001,	****P	<	0.0001
(A) (B)
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infection.45	 Furthermore,	 vaccinating	mice	 with	 a	 chimera	 of	 two	
recombinant	 schistosomula	 antigens	 SmTSP2	 and	 SmLy6D	 (Sm29)	
formulated	 in	CpG-	Alum	also	protects	vaccinated	mice	against	 in-
fection.46 Whether the schistosomula antigens used in the present 
study,	SmLy6B,	SmTSP6	and	SmTSP7,	are	protective	in	animal	mod-
els	of	schistosomiasis	remains	to	be	determined.	In	a	study	in	Brazil,	
Sm14-	specific	Th1	responses	were	produced	by	PBMCs	of	people	
who were resistant to reinfection with schistosomiasis.40	This	sug-
gests	that	high	antigen-	specific	Th1	responses	may	play	a	protective	
role	in	human	resistance	to	reinfection.	However,	with	no	clear	re-
sistant	group	in	our	cohort	1-	year	post-	treatment,	we	instead	looked	
at	the	association	between	cytokine	responses	and	infection	inten-
sity	before	and	after	treatment	with	PZQ.	We	found	no	association	
between	 infection	 intensity	 at	 either	 pre-	 or	 post-	treatment	 and	
that	 Th1/pro-	inflammatory	 cytokines	 to	 rSmLy6B,	 rSmTSP6	 and	
rSmTSP7	 suggesting	 that	 in	 our	 cohort	 these	 responses	 may	 not	
be protective in humans and other schistosomula antigenic targets 
should	be	explored.
Recombinant	 SmLy6B,	 rSmTSP6	 and	 rSmTSP7	 induced	 produc-
tion	of	regulatory	cytokines	IL-	10	and	IL-	1ra.	This	is	consistent	with	
work	done	with	 another	 schistosomula	 tegument	 antigen,	 SmLy6D	
(Sm29),	 that	 induced	 IL-	10	 production	 in	 PBMCs	 of	 S. mansoni-	
infected individuals.41	 In	 fact,	 the	 expression	 of	 SmLy6D	 (Sm29)	 is	
similar	to	that	of	rSmLy6B16,19	and	rSmTSP6	and	rSmTSP7.19	The	con-
comitant regulatory responses induced by the recombinant antigens 
in the present study may be needed to balance effector responses 
F IGURE  4 Unsupervised	hierarchical	clustering	of	cytokine	responses	from	PBMCs	of	Schistosoma mansoni-	infected	participants	(n	=	54)	
before	PZQ	treatment	stimulated	with	S. mansoni schistosomula antigens. Red and blue colours indicate strong positive and negative 
correlations respectively
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to	 limit	 immunopathology.	 This	 suggests	 that	 antigens	 rSmLy6B,	
rSmTSP6	and	 rSmTSP7	 that	 induce	 regulated	Th1	 responses	might	
be good targets to consider further as prospective human vaccine 
candidates	 in	combination	with	adjuvants	to	 induce	a	stronger	Th1	
response.	 In	 the	 present	 study,	 rSmKK7	 did	 not	 significantly	 pro-
duce	IL-	10.	However,	IL-	10	has	been	shown	to	be	elevated	in	patients	
stimulated	with	cercarial	excreted-	secreted	(ES)	products47 of which 
SmKK7	is	a	component.16	This	inconsistency	suggests	that	other	con-
stituents	of	cercarial	ES	material	could	be	the	major	stimulants	of	IL-	
10	production.	In	fact,	glycosylated	components	of	cercarial	ES	may	
play	a	role	in	the	production	of	IL-	10.47	In	addition,	the	anomaly	in	IL-	
10 production could be caused by a difference in the stimulant used. 
Turner	and	colleagues	used	native	cercarial	ES	material	released	from	
transforming cercariae,47	while	the	SmKK7	used	in	the	present	study	
is a purified recombinant protein without glycosylated moieties.
Interestingly,	 rSmTSP7	 induced	 IL-	13	 production	 in	 stimulated	
PBMCs	of	 infected	 participants,	whereas	 the	 other	 schistosomula	
antigens	did	not.	 In	addition,	the	same	rSmTSP7	induced	Th1/pro-	
inflammatory	 cytokine	 production.	 These	 findings	 imply	 a	 mixed	
Th1/Th2	 response	 to	 recombinant	 schistosomula	antigen	SmTSP7.	
As	 much	 as	 murine	 studies	 have	 suggested	 that	 Th1	 responses	
against	migrating	larvae	may	be	more	host	protective	than	Th2	re-
sponses,46,48,49	a	mixed	Th1/Th2	response	in	mice	vaccinated	with	
radiation-	attenuated	cercariae	indicates	that	induction	and	balance	
of	both	Th1	and	Th2	are	required	for	vaccine-	induced	protection	and	
not	a	highly	polarized	Th1	or	Th2.50	Unregulated	and	highly	polarized	
immune responses are responsible for the immunopathology associ-
ated with schistosomiasis in mice51 and humans.52	This	property	of	
rSmTSP7	to	induce	a	regulated	mixed	Th1/Th2	response	positions	it	
as a potential vaccine candidate to investigate further.
Recombinant	rSmKK7	and	rSmLy6A	induced	low	responses	and	
suppressed	the	production	of	IL-	17	and	IL-	1ra	compared	to	PBMCs	
cultured	in	medium	alone.	rSmKK7	shares	homology	with	a	venom	
protein	BmKK7	of	the	Asian	scorpion	Buthus martensi	Karsch	(BmK)	
that	blocks	potassium	channels.16,53	As	potassium	channels	are	vital	
in	 the	 regulation	 of	 T	 cell	 activation	 after	 antigenic	 stimulation,54 
it	 is	 possible	 that	 SmKK7	 affects	 potassium	 channels,	 thereby	
modulating	 T	 cell	 activation	 and	 suppressing	 cytokine	 production	
by	T	 cells.16	 It	 remains	 to	 be	 experimentally	 determined	 if	 indeed	
SmKK7	modulates	human	T	cell	activation.	Furthermore,	Th1/pro-	
inflammatory	immune	responses	to	rSmKK7	and	rSmLy6A	were	pos-
itively	associated	with	pre-	treatment	 infection	 intensity.	However,	
the suitability of these antigens as vaccine candidates is debatable 
because they elicited low responses and were not associated with 
protection against S. mansoni reinfection.
The	cytokine	 responses	 to	 the	 recombinant	antigens	observed	
in	 this	 study	 likely	 reflect	 the	differences	 in	 the	expression	of	 the	
gene products of the schistosomula antigens, and their localisation 
within the S. mansoni	organism.	SmLy6B,	SmTSP6	and	SmTSP7	are	
localized	 in	 the	 tegument	 and	 their	 gene	 products	 are	 highly	 ex-
pressed	during	the	3-	,	24-	hour,	3-	and	6-	day	schistosomula	as	well	as	
adult life stages17,19;	SmLy6A,	also	a	tegument	antigen,	is	only	highly	
expressed	 in	 the	6-	day	 schistosomula,	while	 SmKK7	 is	 a	 secreted	
molecule.16
Because	 of	 the	 small	 number	 of	 participants	 in	 the	 present	
analysis, a larger study may be warranted to investigate the asso-
ciation	between	cytokine	responses	to	the	schistosomula	antigens	
and	 infection	 intensity	 1	year	 after	 PZQ	 treatment.	 Nonetheless,	
a	 large	number	of	cytokines	were	evaluated	per	participant.	While	
this	creates	a	problem	of	multiple	comparisons,	the	approach	taken	
in the present study using unsupervised hierarchical clustering al-
lows	for	large	numbers	of	cytokines/	growth	factors/chemokines	to	
be	tested	as	a	group	rather	than	as	 individual	parameters.	The	re-
sponses	to	the	crude	antigens	AWA	and	SEA	were	not	represented	
in the cluster analysis of response to recombinant schistosomula 
antigens.	The	global	test	in	the	present	study	utilised	the	groups	of	
cytokines/growth	factors/chemokines	to	find	a	relationship	with	ei-
ther	pre-	treatment	or	1-	year	post-	treatment	infection	intensity.	The	
global test allowed for a global analysis of responses which may give 
broader	and	generalized	insights.	The	global	test	has	been	used	else-
where to study clusters of microarray gene data and how the gene 
clusters	 relate	 to	 two	types	of	 leukaemia.32 In addition, the global 
test adjusts for multiple comparisons since few groups are tested.32 
In essence, the global test may be useful for studies of cohorts with 
many independent measurements.
The	rate	of	exposure	to	the	Schistosoma through water contact 
is associated with resistance to reinfection with schistosomiasis.55-57 
It	 follows	 that	 exposure	 history	 during	 follow-	up	 is	 an	 important	
variable in the understanding of reinfection with schistosomiasis. 
The	participants	 in	 the	present	 study	might	have	had	varied	 rates	
of	exposure	during	follow-	up,	which	was	not	assessed	in	the	pres-
ent study and thus affecting immune responses to schistosomula 
antigens.	To	control	exposure	to	 infection	in	future,	 immunogenic-
ity studies of vaccine antigens, a controlled human infection model 
(CHIM)	 for	 schistosomiasis,	 could	be	explored.	Hitherto	 the	hook-
worm	was	 the	only	human	helminth	 to	be	studied	 in	CHIM	for	 its	
potential	as	a	vaccine	(NCT01940757).	The	first	CHIM	for	schistoso-
miasis	is	ongoing	with	European	volunteers	using	a	single	sex	(male	
TABLE  3 Association	between	clusters	of	cytokine	responses	to	
schistosomula	antigens	and	pre-	treatment	infection	intensity
Clustera
Pre- treatment infection 
intensityb
1- Year post- treatment 
infection intensityb
Crude Adjustedc Crude Adjustedc
A 0.010d 0.026d 0.060 0.131
B 0.663 0.746 0.550 0.853
C 0.189 0.312 0.178 0.363
D 0.496 0.134 0.262 0.481
E 0.307 0.140 0.810 0.946
F 0.578 0.427 0.912 0.866
aClusters	are	shown	in	Figure	4.	
bGlobal test P-	value.	
cAdjusted	for	age	and	sex.	
dPositive direction of association. 
Bold	text	represents	a	significant	difference.	
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cercariae)	infection	to	assess	safety	and	optimal	dose	of	such	con-
trolled	 infections	 (NCT02755324).	Based	on	the	findings	from	this	
trial,	 future	CHIM	for	 schistosomiasis	 could	 investigate	human	 re-
sponses to promising Schistosoma antigens including schistosomula 
antigens in endemic populations.
In conclusion, our findings show that the schistosomula antigens 
rSmLy6B,	rSmTSP6	and	rSmTSP7	induce	a	predominantly	Th1/pro-	
inflammatory	response.	The	recombinant	antigens	SmLy6B,	SmTSP6	
and	SmTSP7	might	be	good	targets	to	investigate	further	as	vaccine	
antigens against S. mansoni infection.
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